Home > Insider Trading > Filing (0001493152-22-023380)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1642380	Oncocyte Corp	OCX	In Vitro & In Vivo Diagnostic Substances (2835)	271041563

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1940797	Peter John Gutfreund	C/O Oncocyte Corporation 15 Cushing Irvine CA 92618		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock, No Par Value	Acquisiton	2022-08-15	10,000	$0.00	10,000	No	4	A	Direct
Common Stock, No Par Value	Acquisiton	2022-08-15	25,000	$0.93	25,000	No	4	P	Indirect	See footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	A	Direct
No	4	P	Indirect	See footnote

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Option to Purchase Common Stock	Acquisiton	2022-08-15	45,000	$0.00	45,000	$0.97

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
45,000		2032-08-15	No	4	A	Direct

Footnotes

The Restricted Stock Units shall vest one year from the date of grant, subject to the Reporting Person's continued service as a director of the Issuer from the date of grant until the vesting date or, if earlier, until the next annual meeting of shareholders.
The price of $0.93 per share represents a weighted average of prices ranging from $0.91 to $0.97 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
These securities are held by the minor children of the Reporting Person, and the Reporting Person has voting and dispositive control over such securities.
Options shall vest one year from the date of grant, subject to the Reporting Person's continued service as a director of the Issuer from the date of grant until the vesting date or, if earlier, until the next annual meeting of shareholders.